ozempic and tirzepatide the same In adults with obesity but not diabetes, leads to significantly greater weight loss than semaglutide over 72 weeks, nearly double patients on tirzepatide meet the 25% weight-loss target. http://ms.spr.ly/6183SkuIL Ozempic and Tirzepatide at Vive

Leber's Disease This medicine is not recommended for use in patients who have Leber's Disease, a rare genetic disorder due to the increased risk of worsening the patient's condition

These warnings focus on misleading claims, improper prescribing practices, and the sale of products that may not meet FDA-approved standards

* For optimal protection, Express Shipping is strongly recommended

The four-week interval between dose increases is based on clinical evidence showing it minimizes severe nausea and gastrointestinal side effects while allowing your body to adapt

Visit accredo.com/dodspecialty for more information

We can also help join the growing group of patients suing over Wegovy, ensuring your voice is heard and your rights are protected